Max Kim, MD
Glaucoma Specialist · Phoenix, AZNPI 1851300461
Payments from drug & device makers
Across 445 payments — averaging $1091.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$477K
- Johnson & Johnson Surgical Vision, Inc.$2K
- Aerie Pharmaceuticals, Inc.$1K
- Sun Pharmaceutical Industries Inc.$1K
- Alcon$1K
- Glaukos Corporation$801
- plus $3K from 19 others
What the payments were for
- Travel & lodging$1,39013%
- Food & beverage$8,81985%
- Education$871%
- Gifts$190%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 234 | $476,541 |
| Johnson & Johnson Surgical Vision, Inc. | 5 | $1,703 |
| Aerie Pharmaceuticals, Inc. | 61 | $1,221 |
| Sun Pharmaceutical Industries Inc. | 32 | $1,192 |
| Alcon | 35 | $1,154 |
| Glaukos Corporation | 7 | $801 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 8 | $441 |
| Rxsight Inc | 4 | $368 |
| Bausch & Lomb Americas Inc. | 14 | $292 |
| Dompe US, Inc. | 4 | $287 |
| Eyevance Pharmaceuticals LLC | 5 | $239 |
| Ivantis, Inc | 2 | $225 |
| Thea Pharma Inc. | 10 | $176 |
| Novartis | 4 | $168 |
| Kala Pharmaceuticals, Inc. | 2 | $137 |
| Sight Sciences, Inc. | 2 | $136 |
| Apellis Pharmaceuticals, Inc. | 4 | $107 |
| Genentech USA, Inc. | 1 | $81 |
| Carl Zeiss Meditec USA, Inc. | 1 | $74 |
| Heidelberg Engineering, Inc. | 1 | $68 |
| NEW World Medical,inc. | 5 | $35 |
| Ocular Therapeutix, Inc. | 1 | $26 |
| Akorn Operating Company LLC | 1 | $24 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Rayner Intraocular Lenses Limited | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Tecnis 1-piece IOL$1,683
- Tecnis 3-piece IOL$1,683
- Tecnis Symfony IOL$1,683
- Tecnis Symfony Toric IOL$1,683
- CEQUA$620
- iDoseTR$398
- Rhopressa$332
- Rocklatan$332
- VYZULTA$329
- RXSIGHT CONTACT LENS$249
- RXSIGHT INJECTOR CARTRIDGE$249
- RXSIGHT INJECTOR HANDPIECE$249
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$249
- Hydrus$225
- Flarex$171
- iDose$158
- XEN$147
- AcrySof IQ VIVITY IOL$139
- LIGHT ADJUSTABLE LENS (LAL)$125
- TRAVATAN Z$124
How this compares
Too few glaucoma specialist providers in Arizonato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 452 | $253,623 |
| RhopressaNetarsudil Mesylate | 257 | $107,207 |
| Alphagan PBrimonidine Tartrate | 164 | $70,739 |
| CombiganBrimonidine Tartrate/Timolol | 85 | $48,363 |
| RocklatanNetarsudil Mesylat/Latanoprost | 103 | $43,121 |
| VyzultaLatanoprostene Bunod | 66 | $28,907 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 95 | $24,175 |
| RestasisCyclosporine | 25 | $21,507 |
| Travoprost | 109 | $17,694 |
| Brinzolamide | 62 | $15,737 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 931 | $14,915 |
| AzoptBrinzolamide | 20 | $13,732 |
| Latanoprost | 1,149 | $12,797 |
| CequaCyclosporine | 13 | $12,548 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 49 | $8,907 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Alphagan P, Combigan, Restasis | $476,541 | $394,232726 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $1,221 | $150,328360 claims |
| AlconSimbrinza, Azopt | $1,154 | $37,907115 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $292 | $28,90766 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $1,192 | $12,54813 claims |
| NovartisTravatan Z | $168 | $6,07613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few glaucoma specialist providers in Arizonaon file to place this against a meaningful peer group, so we don't.
Other glaucoma specialist in Phoenix
- Christine FunkePhoenix$451K
- Neil AtodariaPhoenix$97K
- Tara GolischPhoenix$3K
- Howard BerlinPhoenix$937
- Andrew RabinowitzPhoenix$396
- John LewisMesa$61K
- Robert SpurnyMesa$5K
- David KayMesa$4K
- Trenton BowenGilbert$4K
- Michael CampionScottsdale$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.